CANC Profile
The Tema Oncology ETF (CANC) is a dynamic exchange-traded fund ("ETF") specializing in health care equity investments, particularly focused on companies dedicated to cancer treatment and management globally. Managed actively by Tema, CANC strategically selects stocks using a bottom-up approach, identifying innovative companies poised for growth and perceived to be undervalued relative to their market potential. This approach allows CANC to capitalize on emerging trends and advancements in oncology, aiming to deliver competitive returns while managing risk effectively within the healthcare sector.
Launched on August 15, 2023, CANC underscores Tema's commitment to providing investors with targeted exposure to the oncology sector, leveraging its expertise in healthcare investments and rigorous research methodologies. The ETF's active management strategy enables Tema to dynamically adjust its portfolio composition based on market dynamics and company-specific developments, ensuring alignment with evolving investor preferences and industry trends.
CANC's investment mandate extends beyond geographic boundaries, encompassing a diverse range of issuers involved in cancer treatment and related therapies. By focusing on companies at the forefront of oncology innovation, CANC offers investors an opportunity to participate in the growth potential of the global healthcare market while emphasizing sustainability and long-term value creation. Tema's dedication to transparency, liquidity, and investor education further enhances CANC's appeal as a strategic investment vehicle within the healthcare ETF landscape.
Tema's issuance of CANC exemplifies its role as a trusted steward of investor capital, committed to delivering robust investment solutions that address specific sectoral demands and contribute to overall portfolio diversification. With a steadfast focus on identifying promising healthcare companies and leveraging market insights, Tema continues to position CANC as a premier choice for investors seeking exposure to the dynamic and critical field of oncology research and treatment.
|
